...
....
Pharmaceutical
Biotechnology

> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
Industrial
Biotechnology
> See specialized channels


  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter
Back to PRESS RELEASES - 

Definiens Strengthens Leadership with Key Appointment

| Print |
Tuesday, 31 January 2012 17:00 (UTC + 1)

definiens_logo

Former Aperio Executive and Digital Pathology Market Expert, Dr. Martin Stuart, Joins Executive Team

Munich, Germany, January 31, 2012 / B3C newswire / - Definiens, the global leader in Health Image Intelligence and Quantitative Digital Pathology, has appointed Martin Stuart, PhD, as its Executive Vice President and General Manager North America and Asian Pacific. In his new role, Stuart will be responsible for expanding the Definiens business in North America and Asia and providing leadership to the sales and field operations. 

Martin Stuart, a former Senior Vice President and General Manager of Aperio, is one of the most influential leaders in the Digital Pathology industry. He has more than 25 years of experience in international sales and marketing, specializing in the introduction of new and disruptive technologies. In his previous global sales and marketing position he was a key driver in making Aperio the leading provider of digital pathology, with more than 850 deployed slide scanner systems in more than 30 countries. Prior to Aperio, Stuart was Global Vice President of Sales and Services for Entropia Inc., a desktop grid computing company focused on the Life Sciences market. 

"I’m excited to join the market leader in Quantitative Digital Pathology" comments Stuart. "Image analysis is a major driver of adoption and I’m extremely impressed by the results customers are getting by deploying Definiens products and solutions. There is enormous demand for solutions that help pathologists deal with the increasing complexities of their discipline as they support the transition to personalized medicine. I see Definiens as best positioned to address this demand by providing comprehensive decision support solutions."

"We are extremely pleased to have Martin join Definiens at a time when demand for our products is growing rapidly" says Thomas Heydler, CEO of Definiens.  "His executive experience in the digital pathology business coupled with a profound domain background makes him an ideal fit for our team. With this appointment we will significantly increase both our Life Sciences and our Healthcare Business."

 
About Definiens
Definiens is a leading Health Image Intelligence™ company that develops software solutions for biomedical image analysis, data mining and clinical decision support. The company’s software analyzes images from cell-based assays, whole tissue slides and full body scans and allows users to correlate this information with data derived from other sources. By automating analysis workflows and generating new knowledge, Definiens provides pharmaceutical and biotechnology companies, research institutions, clinical service organizations and medical professionals with deeper insights, faster results and better decision support. Harnessing the power of image intelligence, Definiens supports the development of personalized medicine and aims to significantly improve the quality of patients’ lives.

Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at www.definiens.com.


Media Contact
Definiens, Inc.
Dr. Martin Baatz
Vice President Marketing
This e-mail address is being protected from spambots. You need JavaScript enabled to view it